Improving the cost-effectiveness equation of cascade testing for familial hypercholesterolaemia
Open Access
- 1 June 2015
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Lipidology
- Vol. 26 (3) , 162-168
Abstract
Many international recommendations for the management of familial hypercholesterolaemia propose the use of cascade testing using the family mutation to unambiguously identify affected relatives. In the current economic climate DNA information is often regarded as too expensive. Here, we review the literature and suggest strategies to improve cost-effectiveness of cascade testing. Advances in next-generation sequencing have both speeded up the time taken for a genetic diagnosis and reduced costs. Also, it is now clear that, in the majority of patients with a clinical diagnosis of familial hypercholesterolaemia in whom no mutation can be found, the most likely cause of their elevated LDL-cholesterol (LDL-C) is because they have inherited a greater number than average of common LDL-C raising variants in many different genes. The major cost driver for cascade testing is not DNA testing but treatment over the remaining lifetime of the identified relative. With potent statins now off-patent, the overall cost has reduced considerably, and combining these three factors, a familial hypercholesterolaemia service based around DNA-cascade testing is now less than 25% of that estimated by NICE in 2008. Although all patients with a clinical diagnosis of familial hypercholesterolaemia need to have their LDL-C lowered, cascade testing should be focused on those with the monogenic form and not the polygenic form.Keywords
This publication has 31 references indexed in Scilit:
- A systematic review of economic evaluations of the detection and treatment of familial hypercholesterolemiaInternational Journal of Cardiology, 2013
- Identification and biochemical analysis of a novel APOB mutation that causes autosomal dominant hypercholesterolemiaMolecular Genetics & Genomic Medicine, 2013
- Use of targeted exome sequencing as a diagnostic tool for Familial HypercholesterolaemiaJournal of Medical Genetics, 2012
- Guidelines for the identification and management of patients with familial hypercholesterolaemia (FH): Are we coming to a consensus?Atherosclerosis Supplements, 2011
- Integrating provision of specialist lipid services with cascade testing for familial hypercholesterolaemiaCurrent Opinion in Lipidology, 2010
- Efficacy of statins in familial hypercholesterolaemia: a long term cohort studyBMJ, 2008
- Familial hypercholesterolaemia: summary of NICE guidanceBMJ, 2008
- Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry studyEuropean Heart Journal, 2008
- Genetic causes of familial hypercholesterolaemia in patients in the UK: relation to plasma lipid levels and coronary heart disease riskJournal of Medical Genetics, 2006
- A review on the diagnosis, natural history, and treatment of familial hypercholesterolaemiaAtherosclerosis, 2003